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Purpose
The present study evaluated whether oral supplementation with a branched-chain amino
acid (BCAA) improves the biochemical and amino acid profiles of liver tumor patients under-
going radiotherapy.
Materials and Methods
Patients were randomly assigned to one of 2 groups: a group given oral supplementation
with BCAA granules (LIVACT granules; Samil Pharm Co., Korea, each granule containing L-
isoleucine 952 mg, L-leucine 1,904 mg, and L-valine 1,144 mg) during radiotherapy, or a
placebo group. Physical and biochemical examinations and measurements, including sub-
jective symptoms, Child-Pugh class, body mass index, plasma albumin concentration, and
plasma amino acid profiles were monitored. 
Results
Fifty were enrolled between November 2005 and November 2006. We also analyzed data
from 37 hepatocellular carcinoma (HCC) patients in order to evaluate a more homogenous
group. The two groups of patients were comparable in terms of age, gender, Child-Pugh
score, and underlying hepatitis virus type. Serum albumin, total protein, liver enzymes, and
cholesterol showed a tendency to increase in the BCAA group. In this group, the percentage
of cases that reverted to normal serum albumin levels between 3 and 10 weeks after
administration of BCAA was significantly higher (41.18%) than in the placebo group (p=0.043).
Conclusion
Oral supplementation with a BCAA preparation seems to help HCC patients undergoing
radiotherapy by increasing the BCAA concentration.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies and is the third leading cause of cancer mortality in the
world. It is the second leading cause of cancer death in Korea [1,2].
The first choice in the management of HCC is surgical treatment with
partial hepatectomy for localized solitary resectable HCC. Localized
unresectable cases of HCC may be candidates for chemoembolization,
intra-arterial infusion chemotherapy, cryosurgery, percutaneous ethanol
injection, radioimmunotherapy, radiotherapy, or radiofrequency
ablation [3]. Radiotherapy of HCC, however, has long been over-
looked, because the entire liver cannot tolerate a high dose of radiation
[4,5]. Nevertheless, recent reports reveal that development of 3-
dimensional conformal radiotherapy has been increasingly applied to
HCC management with substantial success [6-12]. 
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Most patients referred for radiation therapy have chronic liver
disease, and their lesions are at an advanced stage that is frequently
associated with a state of protein-calorie malnutrition. In addition, ra-
diation induces toxicities such as abnormal liver function tests. General
fatigue, nausea and vomiting remain a challenge to achieving effective
radiotherapy [13-15]. These adverse effects may further aggravate the
patients’ nutritional status. 
Branched-chain amino acid (BCAA) supplementation has pre-
viously been shown to increase serum albumin levels and the Fischer’s
ratio in cirrhotic patients [16]. Moreover, randomized controlled studies
have demonstrated that parenteral or oral nutritional support with
BCAA-enriched preparations in patients undergoing hepatic resection
for HCC significantly improves their post-operative nutritional status
and reduces morbidity and length of hospital stay [17,18].
Patients with unresectable HCC who have either advanced tumors or
severe cirrhosis are more likely to suffer from malnutrition. Therefore,
oral BCAA support may play an important role in the management of
patients who receive radiation therapy for HCC. However, there have
been no studies on nutritional support in patients undergoing
radiotherapy for HCC. We hypothesized that BCAA support is helpful
for maintaining liver function and nutritional build-up. Therefore, we
designed a double-blind, randomized, placebo-controlled study to
evaluate whether BCAA improves biochemical and amino acid
profiles of HCC patients undergoing radiotherapy.
Materials and Methods
1 Patients
Patients older than 16 years but younger than 75 years with less than
a 30% indocyanin green retention rate at 15 min score were eligible for
this study. Patients with alcohol-induced liver cirrhosis, hepatic
encephalopathy, hepatic failure higher than grade III, serum total
bilirubin higher than 5 mg/dL and obstruction of the extrahepatic bile
duct, or showing reactivation of hepatitis, were excluded. After
providing written informed consent, all subjects received a package of
drugs, which consisted of either BCAA or a placebo, in a double-blind
fashion. This study was approved by our Institutional Review Board,
and was registered under number 4-2005-0112. Primary endpoints
were: serum biochemical and amino acid profiles as a result of re-
ceiving the BCAA supplement; the number of patients that reverted to
normal serum albumin values. Secondary end points included: sub-
jective symptoms and nutritional parameters.
Assumptions for the sample-size calculation were based on the
primary result being a significant increase of biochemical profiles and
amino acid profiles from baseline profiles, or, a significant recovery
from baseline to normal values. We assumed that 50% of patients
treated with BCAA will show a significant increase or recovery of
biochemical profiles and amino acid profiles, and that patients treated
with placebo will improve in 10% of cases. A sample size of 20 pa-
tients per group was needed for the statistical verification of such a
result (significance level α =0.05; power, 90%). After allowing for a
drop-out and withdrawal rate of up to 20%, recruitment of 50 patients
was planned. 
2 Methods 
1) Random oral administration of BCAA and placebo
Patients were randomized (ratio 1 : 1) to receive double-blind
treatment with either BCCA, or placebo during radiotherapy. Patient
randomization was performed using a blindly labeled sachet from
Samil Pharm Co. (Seoul, Korea). Both the BCCA and placebo were
packaged in the sachet. Both were the same shape and contained a
code that was known only to the principal investigator. The contents
were known neither to the participants nor to the physician. Once a pa-
tient signed the study consent, we chose the code number in a regular
sequence. Therefore, patients were randomly administered the placebo
or BCAA in a double-blind fashion. The BCAA group was given a
sachet (4.74 g) of LIVACT (Samil Pharm Co.), which contained 952
mg of L-isoleucine, 1,904 mg of L-leucine, and 1,144 mg of L-valine,
orally three times a day after meals during radiotherapy (5-6 weeks).
The placebo group was given placebo on the same schedule. 
General blood tests (complete blood count and platelets) and plasma
biochemical tests (blood urea nitrogen/creatinine, aspartate ami-
notransferase/alanine aminotransferase, total protein, total bilirubin,
albumin, and cholesterol) were done during the double-blind treatment
period and one month after termination of radiation therapy. Serum
amino acids (isoleucine, leucine, valine, phenylalanine, tyrosine, and
methionine) were measured twice, before and after radiation therapy.
The Fischer ratio (isoleucine+leucine+valine/phenylalanine+tyrosine)
was also calculated. 
Subjective symptoms such as ascites, edema, jaundice, anorexia,
abdominal distension, fatigue, itching sensation, and hepatic en-
cephalopathy were scored before and at the end of radiation therapy,
and one month after the termination of radiation therapy (Fig. 1). We
scored each subjective symptom, according to Muto et al.’s research
[19] from 0 (normal) to 3 (severe). Nutritional evaluation was
performed at baseline and post-radiotherapy by interview with pro-
fessional nutrition teams. Nutritional parameters included dietary
nutrient intake, and anthropometric measures such as body weight,
body mass index (BMI), lean body mass, calorie intake, and protein
intake, etc. Body fat measurement was done using a body fat analyzer
(body fat analyzer model TBF-105, Tanita Co., Tokyo, Japan) based
on the principle of biomedical impedance.
2) Radiotherapy planning and treatment
For radiotherapy planning and treatment, patients were positioned
supine with their arms above their head. The patients had been trained
to breathe as shallowly as possible and had planning computed
tomography (CT) and treatment with free set-up. Helical CT with a 5
mm slice was used for this planning (Picker PQ 5000, Marconi Me-Cancer Res Treat. 2011;43(1):24-31
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Fig. 1. Trial design. Subjects were randomized into branched-chain amino acid (BCAA) and placebo groups. Subjective symptoms, Child-Pugh
score, biochemical profiles, and nutritional states were evaluated. CBC, complete blood count.
Characteristic
BCAA Placebo
group group
p-value
No. of patients 20 17
Sex (male/female) 19/1 15/2
Age (yr) 54.05±11.26 55.69±10.33
Body mass index 23.15±2.60 23.40±2.06
Etiology (HBV/HCV) 20/0 14/3
Child-Pugh class
A  18 17
B2 0
Blood chemistry
Total cholesterol 136.35±40.53 132.94±30.60 0.77
Triglyceride 82.05±34.47 82.24±26.71 0.63
Total protein 6.96±0.74 7.12±0.57 0.62
Albumin  3.74±0.64 3.76±0.47 0.86
Total bilirubin 1.42±2.24 0.91±0.63 0.77
AST 72.55±69.05 57.24±32.03 0.79
ALT 53.80±35.45 56.35±43.82 0.87
Amino acid profiles
Isoleucine 30.17±15.68 21.67±8.55 0.15
Leucine 81.06±29.40 69.33±21.35 0.39
Valine 110.37±33.20 100.06±25.37 0.47
Phenylalanine 29.55±8.18 25.68±7.08 0.24
Tyrosine 41.87±12.13 37.31±12.20 0.25
Fisher’s ratio 3.15±0.79 3.20±1.07 0.60
Score of subjective symptoms 1.65±1.18 2.29±0.69 0.02
Table 2.  Characteristics of subjects enrolled in the trial by rando-
mization status for HCC patients
HCC, hepatocellular carcinoma; BCAA, branched-chain amino acid; HBV, hepatitis
B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
Characteristic BCAA group Placebo group p-value
No. of patients 25 25
Sex (male/female) 23/2 20/5
Age (yr) 55.9±11.0 58.2±9.4
Body mass index 23.4±2.79  22.8±2.1
Blood chemistry
Total cholesterol 136.35±40.53 132.94±30.60 0.77
Triglyceride 82.05±34.47 82.24±26.71 0.63
Total protein 6.96±0.74 7.12±0.57 0.62
Albumin  3.74±0.64 3.76±0.47 0.86
Total bilirubin 1.42±2.24 0.91±0.63 0.77
AST 72.55±69.05 57.24±32.03 0.79
ALT 53.80±35.45 56.35±43.82 0.87
Amino acid profiles
Isoleucine 29.93±15.01 21.70 ±9.10 0.07 
Leucine 77.83±28.16 64.53±25.93 0.11
Valine 109.73±32.71 95.17±31.77 0.14
Phenylalanine 28.04±8.02 24.78±7.32 0.17
Tyrosine 38.93±12.59 36.43±12.30 0.51
Fisher’s ratio 3.33±0.99 3.03±0.93 0.29
Score of subjective 1.88±1.27 2.68±1.84 0.08
symptoms
Table 1. Characteristics of subjects enrolled in the trial by rando-
mization status
BCAA, branched-chain amino acid; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.Ik Jae Lee, et al_Effect of Oral Supplementation with BCAA during Radiotherapy for Hepatocellular Carcinoma
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dical Systems Inc., Cleveland, OH). All gross tumor volumes (GTV)
were contoured on intravenous contrast-enhanced lesions. For a better
delineation of the tumor volume, a hepatic angiographic image was
used as a reference. A minimum of 5 mm around the GTV was in-
cluded in the clinical target volume. In designing the planning target
volume (PTV), the margins were individualized by observing the
position of the liver as well as liver movement at the time of simu-
lation. To verify cranio-caudal motion, we checked diaphragm move-
ment by fluoroscopy before treatment, and radiation therapy was admi-
nistered using a 6 or 10 MV linear accelerator (Varian Medical
Systems, Palo Alto, CA). The radiation dose to the target volume was
determined depending on the functional reserve of the liver and chosen
to be in the range of dose prescription guidelines at each V50%
category. For the guidelines from Yonsei University, if the percentage
of non-tumor liver volume receiving 50% of the isocenter dose was ＜
25%, the total dose was increased to 59.4 Gy; if 25-50%, the dose was
45-54 Gy; if 50-75%, the dose was 30.6-41.4 Gy; and if ＞75%, no
treatment was administered [20]. A total of 45 Gy was usually pre-
scribed in 25 fractions of 1.8 Gy over 5 weeks. We intended to deliver
95% of the prescribed dose encompassing the PTV around the GTV.
A multiport combination of two or more ports was adopted, depending
on the tumor location, and the median total dose was 46.8±9.7 Gy.
3 Statistical analysis
All data are expressed as mean±standard deviation, unless otherwise
indicated. Differences were considered significant when a two-sided p-
value was less than 0.05. The placebo and BCAA groups were com-
pared using the Student’s t-test, and the change in measured values for
each group was analyzed using a paired t-test.
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Fig. 2. Changes in biochemical profiles showing no significant differences between patients treated with branched-chain amino acid (BCAA)
and placebo. (A) Total cholesterol. (B) Serum triglyceride. (C) Serum total protein. (D) Serum albumin (continued to the next page).Cancer Res Treat. 2011;43(1):24-31
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Results
1 Patient characteristics
We tried to enroll patients who had received radiation treatment to
the liver, and fifty patients were enrolled between November 2005 and
November 2006. The characteristics and results of all patients are
described in Table 1. However, HCC patients with liver cirrhosis and
other bile ductal cancer patients without cirrhosis are quite different
with regards to the volume of the liver irradiated, dose of radiation
received, and liver function, and we analyzed 37 HCC patients in order
to conduct an evaluation with a more homogenous group. Of these, 20
patients were assigned to the BCAA group, and 17 to the placebo
group (Table 2). During supplementation with BCAA, one patient died
of hepatic failure and 1 patient in the BCAA group was lost to follow-
up. In the placebo group, 2 patients died of hepatic failure, and 2 were
lost to follow-up. Oral BCAA supplementation was terminated in one
patient due to severe anorexia and nausea. Therefore, 30 patients
completed the entire protocol. In the analysis of biochemical profiles, it
was not possible to evaluate one patient in the placebo group due to
lack of serum sampling. A total of 7 patients (4 patients in the BCAA
group and 3 patients in the placebo group) had missing serum levels in
their amino acid profiles. We enrolled all patients with liver failure and
evaluated them using the intention-to-treat (ITT) and per-protocol (PP)
analysis.
We studied 34 males and 3 females. The mean age was 55.2 years.
Except for 2 patients, hepatic function received a Child-Pugh class A
score. None had hepatic encephalopathy before enrollment in this
study. All had hepatitis B virus infection except for three cases (3 cases
of hepatitis C virus infection in the placebo group). The age and BMI
of the two groups were comparable and HCC patient characteristics are
shown in Table 2. Baseline nutritional status and biochemical profiles
were similar between BCAA and placebo groups, except for subjective
symptom scores. 
2 Effect of BCAA on subjective symptoms, Child-Pugh
score, and anthropometric measurements
Subjective symptoms and Child-Pugh scores showed no significant
differences between BCAA and placebo groups after ITT and PP
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Fig. 2. (Continued from the previous page) (E) Serum aspartate
aminotransferase (AST). (F) Serum alanine aminotransferase
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analyses. No patients developed flapping tremor or hepatic encephalo-
pathy. There were no significant differences in subjective symptoms
such as ascites, edema, jaundice, anorexia, abdominal distension,
fatigue, and itching.
BMI, lean body mass, calorie intake, and protein intake were measured
as nutritional parameters. There was no significant difference in these pa-
rameters between the two groups. Furthermore, there was no trend towards
improvement in these parameters after the administration of BCAA.
3 Effect of BCAA on biochemical profiles
Biochemical profiles, such as mean values of serum total
cholesterol, triglycerides, total protein, and bilirubin were not signi-
ficantly different between the two groups for ITT or PP analyses (Fig.
2). In addition, there were no substantial differences in hemoglobin
concentration and platelet counts. However, there was a slightly higher
tendency in the BCAA group for the cases to return to normal serum
albumin levels. In particular, between the period of 3 and 10 weeks
after the administration of BCAA, the serum albumin levels of 7
patients (of 17 patients; 41.18%) returned to normal values, whereas
only 1 (of 12 patients; 8.33%) in the placebo group returned to normal.
This difference was statistically significant (p=0.043) (Fig. 3).
4 Effect of BCAA on profiles of amino acids
As seen in ITT and PP analyses, there was a slight tendency towards
an increase of amino acids’ serum value and Fisher’s ratio in the
BCAA group (Tables 3 and 4). The number of patients showing im-
proved leucine and valine values increased by 5.36% and 13.39%,
whereas the number of patients in the placebo group showing
improved isoleucine values increased by 19.64% compared with the
BCAA group.
Values for aromatic amino acids such as phenylalanine and
tyrosine showed no substantial differences between the two groups.
Baseline-3
60
(%)
0
Placebo
BCAA
40
20
Baseline-6
Baseline-10
3-6
3-10
6-10(wk)
p=0.043
Fig. 3. Percentage of patients whose serum albumin returned to a
normal level. Serum albumin levels recovered from 3 to 10 wk in the
branched-chain amino acid (BCAA) treatment group (p= 0.043).
BCAA group Placebo group
No. of increased patients % No. of increased patients %
p-value
Isoleucine 9/16 56.25 8/14 57.14 0.961
Leucine 10/16 62.50 8/14 57.14 0.765
Valine 9/16 56.25 6/14 42.86 0.464
Phenylalanine 8/16 50.00 11/14 78.57 0.105
Tyrosine 9/16 56.25 12/14 85.71 0.118
Methionine 6/16 37.50 9/14 64.29 0.143
Fisher’s ratio 11/16 68.75 8/14 57.14 0.510
Table 3.  Changes in the mean serum value of amino acid and Fisher’s ratio for HCC patients (ITT analysis)
HCC, hepatocellular carcinoma; ITT, intension to treat; BCAA, branched-chain amino acid.
BCAA group Placebo group
Group
No. of improved patients % No. of improved patients %
p-value
Isoleucine 9/14 64.29 7/12 58.33 1.000
Leucine 9/14 64.29 7/12 58.33 1.000
Valine 9/14 64.29 6/12 50.00 0.692
Phenylalanine 7/14 50.00 9/12 75.00 0.248
Tyrosine 8/14 57.14 10/12 83.33 0.216
Methionine 5/14 35.71 7/12 58.33 0.431
Fisher’s ratio 10/14 71.43 7/12 58.33 0.683
Table 4.  Changes in the mean serum value of amino acid and Fisher’s ratio for HCC patients (PP analysis)
HCC, hepatocellular carcinoma; PP, per protocol; BCAA, branched-chain amino acid.Cancer Res Treat. 2011;43(1):24-31
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More patients in the BCAA group returned to a normal Fisher’s
ratio than in the placebo group, although the difference did not reach
statistical significance.
Discussion
BCAA constitutes approximately 40% of the essential amino acids
present in the human body. In contrast to other amino acids that are
metabolized in the liver, most BCAA are utilized in muscles and
peripheral tissues. The major clinical effects of BCAA that have been
reported include awakening effect on hepatic encephalopathy and
nutritional supplementation on liver toxicity, and chronic renal failure.
It has generally been considered that the effect of BCAA on hepatic en-
cephalopathy is caused by the impairment of amino acid transport to
the brain through the blood-brain barrier, reduction of ammonia con-
sumption in the brain and muscles, and the acceleration of epinephrine
synthesis in the brain. BCAA has been considered beneficial for
nutritional improvement because BCAA can be used as a calorie
source or accelerate protein synthesis in muscles as well as suppress
protein degradation and accelerate protein synthesis in the liver.
Marchesini et al. [21] did a multicenter randomized study comparing
1 year of nutritional supplementation with BCAA in 174 patients with
advanced cirrhosis. The average time of hospital admission was lower
in the BCAA arm compared with the control treatments (p=0.006 and
p=0.003, respectively). In addition, nutritional parameters, liver func-
tion tests, and the Child-Pugh scores improved in patients treated with
BCAA (p=0.013). However, long-term compliance with taking BCAA
was poor. Our previous prospective comparative study was conducted
to investigate the efficacy of orally administered BCAA in cirrhotic
patients. We found that there was a significant increase in plasma levels
of BCAA in the BCAA group (p＜0.001). Fischer’s ratio also increased
significantly after the administration of oral BCAA (p＜0.001) [22].
A decrease in Fisher’s ratio after resection of liver tumors correlates
with the duration of post-resection hepatic failure [23]. For patients
who had liver cancer complicated by liver cirrhosis and who under-
went surgery, serum albumin levels recovered earlier in the BCAA
group [24]. Nutritional support may also be important in patients
undergoing chemoembolization. Poon et al. showed that nutritional
supplementation using BCAA is effective in reducing morbidity after
transarterial chemoembolization [25].
To the best of our knowledge, this is the first randomized double
blind study to evaluate the efficacy of BCAA supplementation during
radiotherapy. In our study, changes in plasma amino-acid profiles
showed no substantial differences between the BCAA and placebo
groups. However, BCAA had a tendency to increase in the BCAA
group. Changes in Fisher’s ratio also increased slightly after oral
supplementation with BCAA. The proportion of patients in the BCAA
group whose serum albumin recovered to normal levels significantly
increased from 3 to 10 weeks. 
However, our trial had some limitations. In most reports, BCAA
was administered for approximately 2 months to 2 years [21,22,24],
but in our study it was administered only during the period of radiation
therapy (5-6 weeks). Furthermore, the number of patients recruited was
small. Therefore, the change in albumin values or other parameters
might not be significant. Our study was conducted using advanced
HCC patients with liver cirrhosis. It would have been difficult to con-
duct a long-term double-blind randomized study of LIVACT and enroll
enough patients. Therefore, more studies should be conducted to further
elucidate the role of nutritional support in radiotherapy for HCC.
A supplementation study with more cases and a longer intervention
period might be necessary to determine the effect of BCAA on patients
with underlying liver cirrhosis during radiotherapy. In our study, al-
though BCAA was administered for only a short period, it appears that
BCAA supplementation is helpful in restoring albumin levels as well
as Fisher’s ratio in HCC patients receiving radiotherapy. 
Conclusion
Oral supplementation with a BCAA preparation seems to help HCC
patients undergoing radiotherapy by increasing BCAA concentrations.
BCAA supplementation may provide further hope for HCC patients
with low biochemical profiles during radiotherapy.
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